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INTRODUCTION
Cirrhosis  is  associated 
with an increased risk for the 
development of cardiovascular 
diseases. Decreased systemic 
vascular resistance, increased 
cardiac output and abnormal 
myocardial contractile function 
are the characteristic features and 
likely to appear as consequences 
of cirrhosis. The functional 
and structural changes of the 
myocardium have been referred 
as cirrhotic cardiomyopathy 
(CCM), a slow progression 
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AbSTRACT
Hyperdynamic circulation, systolic and diastolic left ventricular dysfunction and certain electrophysiological 
abnormalities have been associated with cirrhosis and known for a long time. These clinical features have been 
introduced as cirrhotic cardiomyopathy (CCM), which is characterized by blunted myocardial contractile 
responsiveness to physical, physiological and pharmacological stress. Importantly, cardiac dysfunction 
can be reversible and can improve due to effective medical treatment and also after liver transplantation. 
Echocardiography and electrocardiography are essential tools for recognizing the characteristic changes in 
the myocardial function and also the alterations in the electrophysiological properties of the heart. Laboratory 
markers are auxiliary modalities further aiding the establishment of the correct diagnosis. In this review, we 
aimed to collect the pathophysiological background and clinical characteristics of CCM with the intention 
of summarizing the current possibilities for the diagnosis establishment and treatment of this cardio-hepatic 
disorder. 
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myocardial dysfunction associated with cirrhosis [1]. Most 
importantly, this condition should not be confused with 
alcoholic cardiomyopathy where the underlying mechanism 
responsible for the structural and functional cardiac 
abnormalities is well defined [2]. In contrast to alcoholic 
cardiac disease, in the case of CCM any well-defined underlying 
provoking factor(s) can be identified; however, sometimes 
iron overload or alcohol consumption may worsen the 
already hampered structural and functional condition of the 
myocardium [3]. In CCM, left and right ventricular contractile 
function may decrease resulting in an altered responsiveness to 
physical, physiological and pharmacological activity, leading 
to the characteristic symptoms of heart failure [4]. Moreover, 
the disturbed ability for relaxation may lead to diastolic 
myocardial dysfunction or even diastolic heart failure. It is 
important to note that, based on the severity of diastolic heart 
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function, patients are relatively asymptomatic. Nevertheless, 
regardless of clinical manifestation, diastolic heart failure is an 
independent risk factor for cardiovascular mortality in both 
symptomatic and asymptomatic patients [5]. Furthermore, 
diastolic dysfunction is an important underlying factor in the 
development of certain arrhythmias, especially in the genesis 
of atrial fibrillation [6]. In the case of CCM, appearance of 
electrophysiological abnormalities may result in an increased 
risk for the development of both atrial and ventricular 
rhythm disturbances. Fortunately, these abnormalities may be 
reversible after liver transplantation [7]. Cardiac dysfunction is 
considered to be multifactorial in chronic liver diseases. In the 
present review, we aimed to collect all the pathophysiological 
and clinical evidence that may help to understand the core 
of CCM in order to assist clinicians to come to a more exact 
diagnosis and establish a better treatment and care strategy 
for patients suffering from CCM in everyday clinical practice, 
surmounting complications, delaying progression and 
diminishing mortality.
ROLe OF THe VASCULAR TONe 
IN THe GeNeSIS OF CIRRHOTIC 
CARDIOMYOPATHY
Portal hypertension and altered liver function may play an 
important role in the change of intracardiac volume and pressure 
conditions in cirrhosis [8, 9]. Variceal bleeding, concomitant 
anemia and the appearance of ascites are among the most 
important factors that contribute to the decreased right and left 
ventricular preload and afterload [10]. Reduction of central and 
arterial blood volumes in combination with arterial hypotension 
can lead to volume- and baroreceptor activation resulting in 
sodium-water retention [11]. The triad of systolic and diastolic 
dysfunction, hyperdynamic circulation and electrophysiological 
abnormalities are important clinical features of CCM. Arteriolar 
vasodilatation with increased cardiac output, low arterial 
blood pressure and decreased systemic vascular resistance 
eventuate the development of hyperdynamic syndrome in 
cirrhosis. Vasodilatation appears in the splanchnic area while 
vasoconstriction is present in the kidneys. These conditions are 
responsible for the decreased effective central blood volume [9, 
12]. High concentration of vasodilators and reduced sensitivity 
to vasoconstrictors play an important role in the genesis of 
vasodilatation in patients with cirrhosis known to be caused by 
various substances. Nitric oxide (NO), tumor necrosis factor-
alfa (TNF-α), endocannabinoids, adrenomedullin, calcitonin 
gene-related peptide (CGRP), and carbon monoxide (CO) 
are the most important mediators in this field [13, 14]. On the 
contrary, a concomitant activation of the sympathetic nervous 
system and the renin-angiotensin aldosterone system (RAAS) 
(noradrenaline, neuropeptide-Y, endothelin-1, angiotensin II, 
and vasopressin) has been observed [15, 16] (Fig. 1). 
Fig. 1. Hyperdynamic circulation is caused by a pathophysiological 
cascade in patients with cirrhosis.
SNS: sympathetic nervous system; RAAS: renin angiotensin 
aldosterone system
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MeCHANISMS FOR ALTeReD 
MYOCARDIAL FUNCTION
Systolic function
In cirrhosis, myocardial dysfunction was found to 
be associated with the severity of liver disease. Systolic 
dysfunction, however, is mostly latent in this patient 
population. The circulatory dysfunction manifests itself as a 
hyperdynamic unloaded heart failure and cardiac output proves 
to be normal or increased at rest in most cases [17]. Reduction 
in myocardial function becomes overt under conditions 
of physical or pharmacological stress [18]. Latent systolic 
dysfunction becomes manifest during the normalization of 
arterial blood pressure [19]. Accordingly, clinical symptoms 
of systolic heart failure may evolve after liver transplantation 
or the placement of a transjugular intrahepatic portosystemic 
shunt (TIPS) [20]. Reduced left ventricular ejection fraction 
was found to be an important determinant for the development 
of the hepatorenal syndrome as well [21, 22]. Several molecular 
abnormalities were identified as the background of systolic 
dysfunction in patients with cirrhosis. Alterations in the beta 
(β)-adrenergic signaling pathway result in a decreased density 
of β-receptors, reduction in G-proteins and consequently a 
decrease in the production of cyclic adenosine monophosphate 
(cAMP) [23]. Furthermore, due to the increased cholesterol 
content the fluidity of the myocardial cell membrane may alter 
and can impair the ion channel functions [24, 25]. Moreover, 
enhanced endocannabinoid signaling has a negative inotropic 
effect [14]. Additionally, NO overproduction exerts a toxic 
effect on the myocardium due to suppressed contractility and 
induced apoptosis [26]. As TNF-α is a major trigger mechanism 
of NO production, high level of this cytokine worsens the 
pathophysiological and clinical status [27]. 
Diastolic function
Decreased left ventricular relaxation is characterized by 
abnormal trans-mitral ventricular filling, increased atrial 
pressure and prolonged isovolumic relaxation [28]. The 
pathophysiological background of the diastolic dysfunction 
in cirrhosis is the increased stiffness of the myocardial 
wall, which is often caused by myocardial hypertrophy and 
fibrosis due to activation of the RAAS [29].  Subendothelial 
edema and increased interstitial collagen deposition play 
a further role in the decreased ability for relaxation [2, 8]. 
Based on the severity of diastolic heart function, patients 
may be relatively asymptomatic. Diastolic dysfunction is an 
underlying factor in the development of atrial fibrillation where 
the pathomechanism is postulated to be due to an increased 
atrial volume load [6]. Despite these pathomechanisms, no 
convenient evidence can be evaluated on the relationship 
between cirrhosis and atrial fibrillation. Previously, Gundling 
et al reported the increased prevalence of atrial fibrillation in 
their cirrhotic cohort compared to the average population [30].
Nevertheless, regardless of clinical manifestation, diastolic 
heart failure is an independent risk factor for cardiovascular 
mortality in both symptomatic and asymptomatic patients [31].
eLeCTROPHYSIOLOGICAL 
AbNORMALITIeS IN CIRRHOTIC 
CARDIOMYOPATHY 
Electrophysiological abnormalities occurring in cirrhosis 
comprise chronotropic incompetence, electromechanical 
uncoupling, and prolonged QT interval [32–34].  
Chronotropic incompetence
In patients with chronotropic incompetence the sinus node 
is not able to respond to physiological and pharmacological 
stimuli. Furthermore, sympathetic overdrive conditions do not 
result in an adequate acceleration of atrial and ventricular rate. 
This is true even in the case of elevated plasma norepinephrine 
concentrations. This phenomenon may appear both in patients 
with alcoholic and non-alcoholic liver disease and correlates 
with the severity of cirrhosis [2, 35, 36]. 
electromechanical uncoupling
In the case of electromechanical uncoupling there is an 
asynchrony between electrical and mechanical systole that 
can lead to an altered contractile function of the ventricular 
myocardium resulting in congestive heart failure [33, 37]. 
Furthermore, the prevalence of electromechanical uncoupling 
is associated with the severity of liver disease depicted by 
Child-Pugh classification [32]. This abnormality has been 
demonstrated to be caused by receptor and post-receptor 
defects [34].
QT interval and dispersion
The QT interval represents the electrical depolarization 
and repolarization of the ventricular myocardium and it 
depends on the ventricular rate: the faster the heart rate the 
shorter it is [38]. Determination of the QT interval can aid 
the selection of the patient population with increased risk for 
the development of life threatening ventricular dysrhythmias 
[39]. The QT interval duration varies between leads on the 
standard surface electrocardiogram. The interlead difference 
of QT intervals is defined as QT dispersion, which is an index 
of the spatial dispersion of the ventricular recovery times, and 
can distinguish between myocardium that is homogeneous 
from myocardium that displays increased prolongation of 
repolarization [40]. Since these electrocardiographic markers 
can predict ventricular arrhythmias and sudden cardiac death 
they are considered to be among the most significant non-
invasive parameters [41]. 
In patients with cirrhosis, the lengthening of the QT 
interval does not seem to be related to the etiology of the 
liver disease, and appears both in alcoholic and non-alcoholic 
subjects [35, 36]. The prevalence of QT prolongation is high in 
patients with cirrhosis and increases with the severity of the 
liver disease. Accordingly, at least 60% of patients with end-
stage liver disease show this electrocardiographic abnormality 
[32]. Contraversely, Baik et al reported that sudden cardiac 
death is rare in cirrhosis, and torsades de pointes was described 
only in a few patients. Therefore, the clinical significance 
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of QT prolongation in cirrhosis still remains to be clarified 
[42]. Prolongation of the QT interval may also worsen after 
TIPS insertion both in cirrhotic and non-cirrhotic portal 
hypertensive patients. Moreover, TIPS insertion was shown 
to be associated with an increased risk of heart failure [43]. 
The aforementioned electrophysiological changes appeared 
as a result of a combination of ion-channel dysfunction, 
plasma membrane abnormalities and β-adrenoceptor and 
post-receptor pathway defects. 
Various ion channel defects in cirrhosis are now associated 
with the prolongation of the action potential of the myocardial 
cells, which results in the extension of ventricular systole or 
a prolonged QT interval [44, 45]. The electrical properties 
of the myocardial cells largely depend on the duration of 
the monophasic action potentials, which are generated by 
special types of voltage gated ion channels placed in the 
myocardial cells’ plasma membrane. These channels begin to 
open when the membrane potential passes a threshold value. 
During depolarization an inward flow of sodium ions appear, 
which results in a further rise in the membrane potential. 
Consequently, more channels will open (calcium channels), 
leading to a greater electric current across the myocardial 
cells’ membrane. The polarity of the plasma membrane then 
turns to be reversed and the ion channels will rapidly become 
inactivated. Afterwards, an outward current of potassium ions 
(outward rectifier) will return the electrical transmembrane 
gradient to the resting state (repolarization) (Fig. 2). The 
plateau phase of the action potential depends on the balance 
between the efflux of potassium and the influx of calcium 
currents determining the repolarization time of the myocardial 
cell [46]. Impaired function of potassium channels in animal 
models of cirrhosis has been reported leading to a prolongation 
of the action potential, suggesting an increase in the transmural 
heterogeneity of repolarization [47].
Bacterial infections commonly appear in patients with 
cirrhosis. As the inflammation progresses cardio-depressant 
substances such as cytokines, endogenous cannabinoids, and 
nitric oxide are released [48]. The urokinase-type plasminogen 
activator receptor (suPAR) has recently been suggested to bear 
prognostic information [49]. These mediators may influence the 
activation of the inward calcium current leading to an increase 
in the duration of the monophasic action potential. Moreover, 
endothelin (which is elevated in cirrhosis) was shown to induce 
alterations in ion currents of myocardial cell preparations [50]. 
Also, increased bile acid levels (biliary cirrhosis) may modulate 
membrane fluidity causing the changes in ion channel activity 
and the alterations of β-adrenoceptor and G-protein function. 
Increased sympathetic nervous system activity in the presence 
of potassium channel defects may play a role in the genesis 
of inhomogeneous repolarization. Non-selective β-blockade 
may have a favorable effect on QT interval duration in patients 
with cirrhosis, which can be secondary to the improvement 
in hyperdynamic circulation and decreased portal pressure. 
In addition, the enhanced role of sympathetic activity in the 
genesis of myocardial dysfunction in cirrhosis was shown by 
Bernardi et al: a direct correlation between QTc and plasma 
norepinephrine was found that was absent during β-adrenergic 
blockade [32, 51].
However, Zambruni et al reported that chronic 
administration of a non-selective β-blocker was effective in 
reducing the QT interval only in patients with a prolonged 
baseline value.  In patients with normal baseline values, the 
QT interval was not found to be changed by β-blockade. 
Accordingly, the exact role of chronic β-adrenoceptor blockade 
in the arrhythmogenesis in cirrhotic patients is not fully 
elucidated and needs further investigation [52].
DIAGNOSIS
Clinical symptoms
Since cardiac function is nearly normal at rest, the diagnosis 
of this disorder is not easy. In most cases this condition is well 
tolerated and may be asymptomatic for a long period of time, 
and it is often impossible to distinguish the clinical signs and 
complaints from those of the underlying disease. Most of the 
patients are diagnosed during the worsening of the liver disease 
Fig. 2. The monophasic action potential of the myocardial cell is shown. The plateau phase largely 
depends on the potassium and the calcium ion channel activity. The longer the plateau phase, the 
more increased the myocardial cell’s repolarization.
Cirrhosis and cardiomyopathy 5
J Gastrointestin Liver Dis, September 2014 Vol. 23 No 3
when the main clinical characteristics of diastolic heart failure 
and high-output heart failure usually appear. The decrease of 
systolic ventricular competence may enhance the development 
of complications, such as sodium and water-retention, ascites 
formation and worsening of the kidney function [53]. 
Laboratory markers
The determination of natriuretic peptides plays an 
important role in the diagnosis of heart failure. Atrial natriuretic 
peptide (ANP) is released from the atrial myocardium due 
to intracardiac volume overload. Consequently, atrial wall 
stretch is augmented resulting in higher serum levels of this 
biomarker. Since decompensated cirrhosis eventuates altered 
intracardiac volume and pressure conditions, ANP is likely to 
be elevated in these particular cases [54, 55]. Brain natriuretic 
peptide (BNP) and its pro-hormone (pro-BNP) are useful in 
the diagnosis of myocardial injury, and have been shown to be 
elevated in patients with cirrhosis. Moreover, these correlate 
with the stage of the liver disease and may show the severity of 
myocardial dysfunction and ventricular hypertrophy. Despite 
these favorable features BNP and pro-BNP may not be able 
to indicate the hyperdynamic circulation [56, 57]. These 
biomarkers have also been shown to be helpful in the screening 
of CCM [58]. Another laboratory marker, high sensitive 
troponin I seems to be valuable in the risk stratification of 
patients undergoing transjugular intrahepatic portosystemic 
shunts [59]. Recently, a novel plasma biomarker, the galectin-3 
has been shown to mediate myocardial fibrosis and to be 
expressed in cirrhosis. Furthermore, galectin-3 binding protein 
concentrations have also been found to be increased in patients 
with cirrhosis [60].
echocardiography
Assessment of systolic function
The left ventricular systolic performance highly depends 
upon its contractility. Additionally, ventricular pre- and 
afterload, and heart rate have an influence on the myocardial 
contractile power. The ejection fraction (EF) is known to be 
the best marker of the left ventricular systolic function. It is 
known to be a predictor of cardiovascular outcomes, including 
sudden cardiac death in patients with symptomatic heart 
failure [61]. For the evaluation of ejection fraction linear 
measurements (Teicholz or Quinones) can be performed by 
means of a two-dimensional echocardiography [62]. These 
methods require certain geometric assumptions, therefore 
they are not recommended to be used in the everyday clinical 
practice. Instead, the ejection fraction can be calculated more 
exactly from the difference between the end-diastolic and 
the end-systolic left ventricular volume, divided by the end-
diastolic volume (Simpson’s method) [63] (Fig. 3). Finally, 
speckle tracking, another echocardiographic method evaluates 
the frame-to frame tracking of the ventricular myocardium in 
radial, circumferential and longitudinal axis. This  can provide 
a sensitive description of left ventricular systolic function [64]. 
Furthermore, new research is going on with the development 
of new techniques related to echocardiography, which in 
the future will improve this diagnostic method. Finally, 
radionuclide scintigraphy (MUGA - Multi Gated Acquisition 
Scan) can provide highly reliable values of left ventricular 
ejection fraction when echocardiography is uncertain [65].
Evaluation of diastolic function
Left ventricular relaxation abnormalities may be diagnosed 
with echocardiography, too. Even the asymptomatic diastolic 
dysfunction can be recognized at an early disease stage and 
therapy can be started without delay. Moreover, another 
echocardiographic entity, isolated diastolic dysfunction (heart 
failure with normal ejection fraction) can be recognized. 
For the evaluation of diastolic function the transmitral flow 
velocities are measured in early diastole and late diastole 
(presystole) with the help of a pulsed wave Doppler technique. 
The early diastolic transmitral peak flow velocity (E) can be 
determined from the apical four-chamber view. The peak flow 
velocity in the late diastolic period during the atrial contraction 
(A) is also determined. The time between the peak and the end 
of the E-wave deceleration slope is defined as deceleration time 
(DT) [66] (Fig. 4). Using Tissue Doppler Imaging (TDI) the 
Fig. 3. Evaluation of the left ventricular systolic function 
by means of echocardiography during volumetric 
measurements. The determination of the left ventricular 
diastolic volume from the four-chamber apical view 
(Simpson’s method) is shown.
Fig. 4. Transmitral flow velocities measured with the 
help of a pulsed-wave Doppler technique. The ratio of 
early diastolic peak velocity (E) and late diastolic velocity 
(A) is less than 1. The deceleration time (DT) lasts from 
the peak till the end of the E-wave (shown in yellow). 
It is measured to be lengthened (310 msec). These data 
suggest a diastolic dysfunction (relaxation disorder). 
In patients with cirrhosis E/A ratio is usually markedly 
reduced (E/A < 1) and the deceleration time is prolonged 
(DT > 240 msec).
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early diastolic velocity of the septal mitral annulus (Ea) from 
the apical approach can be examined. In order to estimate the 
left ventricular filling pressure the ratio of the E and Ea (E/
Ea) is also calculated. First degree (mild) diastolic dysfunction 
(DD) is defined as: E/A < 0.8, E/Ea < 8, DT > 200 msec and 
second degree (medium) DD as: 0.8 < E/A < 1.5, 8 < E/Ea < 
13 and the DT is 160-200 msec. The criteria for third degree 
(severe) DD are: E/A > 2, E/Ea > 13, DT < 160 msec [67, 68]. 
The diastolic dysfunction in cirrhosis is most pronounced in 
patients with ascites [28, 53].
Electrocardiography
The evaluation of the 12-lead surface electrocardiogram 
of patients with cirrhosis is useful in the recognition of pulse 
generation and/or conduction disturbances, and cardiac 
arrhythmia markers can also be examined. The QT interval is 
one of the most important electrocardiographic parameters for 
the description of ventricular repolarization in patients with 
cirrhosis. Numerous diseases may result in the prolongation 
of this arrhythmia marker (amyloidosis, sarcoidosis, carcinoid, 
hemochromatosis, diabetes mellitus, thyroid dysfunction or 
Parkinson’s disease) [69–74]. In addition, the QT interval may 
be affected by genetic causes (long QT syndrome, short QT 
syndrome). The prolongation of the QT interval may be the 
consequence of drug interaction (e.g. haloperidol, methadone, 
amiodarone, sotalol, selective serotonin reuptake inhibitors, 
macrolide antibiotics, antifungal agents) [75]. Since this 
repolarization marker may be affected by various causes, the 
clarification of the patient’s history is one of the key points in 
the arrhythmia risk determination. 
Considering the required standards for precision, 
measurement of the QT interval still remains subjective 
because the end of the T wave cannot always be exactly defined 
[76]. QT interval may be measured manually by using the 
threshold method, where the end of the T wave is the point 
at which the T wave intercepts the isoelectric line. During the 
tangent method the end of the T wave is determined by the 
intersection of a line determined from the tangent line and 
the isoelectric line. The tangent line is defined as the terminal 
part of the T wave at the point of maximum downslope [77]. In 
order to get more exact data, three consecutive sections can be 
defined, then their average is calculated and the resulting value 
used as the QT interval in the given electrocardiographic lead 
(Fig. 5). The QT interval depends on the ventricular rate (the 
faster the heart rate the shorter the QT interval). Therefore the 
QT interval should be corrected to the heart rate (QTc). There 
are numerous methods that may provide the correction of this 
parameter. Bazett‘s formula is one of the most important in this 
field (QTc= QT/√RR) [78]. The QTc>450 msec value shows an 
increased risk of ventricular arrhythmias [79]. Interestingly, in 
patients with cirrhosis this formula does not clearly describe 
the relationship between the QT and heart rate. Therefore a 
specific ‘cirrhosis formula’ has been derived, which is similar to 
the Friderica’s, and can be confidently used in this setting [80]. 
In order to eliminate the inter-observer variability, during the 
manual measurements values may be calculated with calipers 
by one examiner [40].
THeRAPeUTIC APPROACH TO 
CIRRHOTIC CARDIOMYOPATHY
Impaired cardiac output in patients with CCM may result 
in an altered renal perfusion contributing to the pathogenesis 
of the hepatorenal syndrome.
In addition, due to the decrease in cardiac output, the 
sympathetic tone increases contributing to the activation of 
renal sodium and water retention, and also to the activation of 
the RAAS. Diastolic myocardial dysfunction can contribute to 
an elevated ventricular pressure. The consequently decreased 
circulatory volume can cause a further increase in sodium 
retention. Therefore, the increased sodium excretion mainly 
through aldosterone-blockers and diuretics can result in an 
improved cardiac function. As of now, no generally accepted 
protocol and clinical trials on the management of CCM are 
available. Consequently, patients should be treated following 
the guidelines for non-cirrhosis induced heart failure [2].
Angiotensin converting enzyme (ACe) inhibitors 
Patients with cirrhosis on ACE inhibitor therapy could 
attain long term clinical benefits, but currently no studies are 
available to prove their efficacy in CCM. According to the latest 
Fig. 5. The manual measurement of the QT interval of the 12-lead surface 
electrocardiogram. The calculation and averaging of three consecutive sections 
may provide a more accurate result in the given lead.
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guideline, ACE inhibitors should be administered in patients 
with heart failure, unless contraindicated, in order to reduce 
morbidity and mortality. Data obtained from previous clinical 
investigations have shown no differences regarding clinical 
symptoms and survival among available ACE inhibitors. 
Management should be started at low doses, with gradual 
dose increments. Renal function and serum potassium should 
be monitored periodically especially in patients with renal 
impairment. It is also important to know that ACE inhibitor 
administration in patients with Child Pugh A cirrhosis is 
safe, but not in more severe stages, due to the reduction in 
glomerular filtration rate [81, 82].
Angiotensin-II receptor blockers
Though angiotensin receptor blockers (ARB) have been 
shown to increase sodium excretion without significantly 
affecting renal and systemic hemodynamics, they have not 
yielded beneficial clinical effects in long-term management 
of patients with cirrhosis [83].
Loop and thiazide diuretics
Only diuretics can effectively control the fluid retention of 
patients suffering from heart failure. Therefore, the appropriate 
administration of these drugs is one of the key elements of the 
treatment of these individuals, while inappropriately low doses 
will result in a fluid retention. On the other hand, the incautious 
use of high doses can lead to hypovolemia, hypotension and 
kidney failure. Loop diuretics (e.g. furosemide) are considered 
to be the diuretic agents for most patients with heart failure. 
Thiazide diuretics may be useful in hypertensive patients 
with the symptoms of moderate fluid retention since their 
administration results in a more pronounced antihypertensive 
effect [81].
Aldosterone receptor antagonists 
Hyperaldosteronism is present in nearly all patients with 
cirrhosis and heart failure. Aldosterone may have various 
harmful effects on the myocardium and the cardiovascular 
system [16]. Consequently, mineralocorticoid receptor 
antagonists may be among the first choices of therapy [84]. 
They can improve the hemodynamic properties of patients 
with cirrhosis and may decrease the severe symptoms of 
heart failure [85]. According to the data obtained from the 
RALES (Randomized Aldactone Evaluation Study) trial, a 30% 
reduction in all-cause mortality and a reduced risk of sudden 
cardiac death can be reached with the use of spironolactone 
in patients with chronic heart failure (left ventricular EF 
<35%) [86]. The selective aldosterone blocker, eplerenone 
has also been shown to reduce cardiovascular deaths and 
hospitalizations due to heart failure in a wider range of 
patients [87]. Therefore, aldosterone receptor antagonists 
are useful therapeutic tools in the management of patients 
with symptomatic heart failure and reduced left ventricular 
ejection fraction. Importantly, the careful monitoring of serum 
potassium and renal function can help to avoid the danger 
of hyperkalemia and renal insufficiency. A beneficial effect 
of the aldosterone antagonist, K-canrenoate has been shown 
to reverse myocardial fibrosis in patients with pre-ascitic 
cirrhosis [81, 88].
beta-receptor blockers
The beta-adrenoceptor blockers, especially the non-
selective ones (propranolol, nadolol) are effective in reducing 
portal hypertension and thus in the prevention of the 
gastroesophageal bleeding. More recently, carvedilol – a 
vasodilator, non-selective beta-blocker (NSBB) with intrinsic 
anti-alfa adrenergic activity – has been reported to have greater 
effect on decreasing portal hypertension than propranolol or 
nadolol. Additionally, beta-blockers can improve the cardiac 
contractile function [89, 90]. At the same time, no studies 
on beta-blockers for CCM are available so far. Beta-receptor 
blockers may be one of the choices of treatment since more 
trials showed their effectiveness in the reduction of mortality 
in patients with systolic heart failure [51, 91]. Bisoprolol, 
metoprolol succinate and carvedilol have been proven to be 
the most effective in this field. Due to the beneficial effect of 
carvedilol on portal hypertension, this agent could be the first 
consideration in CCM [81]. Furthermore, long-term treatment 
with beta-blockers can decrease the symptoms of heart failure, 
and improve the patient’s clinical status. Management with 
beta-blockers should be initiated at low doses, and patients 
should be carefully monitored, since therapy may result in 
fluid retention and worsening heart failure, bradycardia, pulse 
conduction abnormalities and hypotension. Even if symptoms 
do not improve, long-term treatment should be maintained in 
order to reduce cardiovascular mortality [81, 92]. In addition, 
NSBBs have been proven to restore lengthened QT intervals 
towards normal in patients with cirrhosis [51]. Despite all these 
beneficial clinical data currently no definitive recommendation 
for the chronic administration of beta-blockers can be made 
in patients with cirrhosis.
Transjugular intrahepatic portosystemic shunt (TIPS)
Since TIPS can rapidly shift a significant amount of blood 
from the splanchnic area to the heart, it may result in a sudden 
worsening of the cardiac function in patients with cirrhosis, 
especially in individuals with impaired diastolic function [93].
Liver transplantation
Liver transplantation is known to be a solution for 
liver failure due to cirrhosis. Interestingly, it seems to cure 
the associated cardiomyopathy as well [20]. Previously, 
amelioration of left ventricular hypertrophy, diastolic 
(lusitropic) dysfunction and normalization of the contractile 
function after transplantation have been reported [7]. 
Prolonged QTc has also been shown to be reversible by 
liver transplantation, despite remaining lengthened right 
after the surgery [94]. On the contrary, orthotropic liver 
transplantation may cause severe hemodynamic consequences, 
since it can result in an abrupt decrease in cardiac output due 
to the clamping of the inferior vena cava. Moreover, a post 
reperfusion injury, secondary coagulopathy, and post-operative 
hydrostatic pulmonary edema may worsen the clinical outcome 
[95]. In addition, cirrhotic patients with concomitant severe 
cardiomyopathy may benefit from cardiac transplantation [96].
Farnesoid X receptor agonists
Novel therapeutic attempts are aiming to increase the 
intrahepatic concentration of vasodilators. Farnesoid X 
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receptor agonists are responsible for hydrogen sulfide 
production; moreover, NCX-1000 may release NO in the 
liver [97]. These agents are promising for future therapeutic 
regimens but their exact role is not yet elucidated in CCM. 
CONCLUSIONS
Currently, there is no single diagnostic tool that can help 
to identify patients with CCM. Patients with symptoms of 
heart failure suffering from cirrhosis should undergo a cardiac 
screening to clarify the structural and functional properties of 
the heart. We emphasize that an early recognition of systolic or 
diastolic myocardial dysfunction by means of echocardiography 
may help to prevent the patient from further worsening of his/
her clinical status. Furthermore, electrocardiography can help to 
recognize the increased risk for arrhythmias and sudden cardiac 
death. Natriuretic peptides may attract attention to the altered 
intracardiac pressure and volume conditions, while novel 
laboratory markers may reflect cardiac and hepatic fibrosis. 
Evidence for cardiomyopathy should be suspected in patients 
with worsening symptoms and clinical results, who may benefit 
from a proper treatment of the underlying pathology. At present 
the management of CCM should follow the recommendations 
for the treatment of patients with heart failure. Further 
investigations may help to improve our knowledge on cardiac 
consequences of liver diseases.
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